Prolongation of the QTc interval in HIV-infected individuals compared to the general population.

about

Prolongation of the QTc interval in HIV-infected individuals compared to the general population.

Item

http://www.wikidata.org/entity/Q40095042

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Prolongation of the QTc interv ...... red to the general population.

@en

type

Item

label

Prolongation of the QTc interv ...... red to the general population.

@en

prefLabel

Prolongation of the QTc interv ...... red to the general population.

@en

P1476

Prolongation of the QTc interv ...... red to the general population.

@en

P2093

Anna Warnke

http://www.w3.org/2001/XMLSchema#string

Christina Schulze

http://www.w3.org/2001/XMLSchema#string

HIV HEART Study Group and the Heinz Nixdorf Recall Investigative Group

http://www.w3.org/2001/XMLSchema#string

Lewin Eisele

http://www.w3.org/2001/XMLSchema#string

Marie Henrike Geisel

http://www.w3.org/2001/XMLSchema#string

Marina Arendt

http://www.w3.org/2001/XMLSchema#string

Nico Reinsch

http://www.w3.org/2001/XMLSchema#string

Norbert H Brockmeyer

http://www.w3.org/2001/XMLSchema#string

Stefan Esser

http://www.w3.org/2001/XMLSchema#string

Till Neumann

http://www.w3.org/2001/XMLSchema#string

P2860

Efavirenz-associated QT prolongation and Torsade de Pointes arrhythmia.

Risk stratification in the long-QT syndrome.

Drug-induced prolongation of the QT interval.

QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.

Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group.

Prolonged QT interval and torsades de pointes associated with atazanavir therapy.

Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat.

Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

P2888

s15010-017-1053-9

P304

659-667

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S15010-017-1053-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28776165

http://www.w3.org/2001/XMLSchema#string